for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Pfizer Inc.

PFE.N

Latest Trade

35.12USD

Change

-0.10(-0.27%)

Volume

3,477,443

Today's Range

34.88

 - 

35.42

52 Week Range

27.89

 - 

43.22

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
35.21
Open
35.34
Volume
3,477,443
3M AVG Volume
585.66
Today's High
35.42
Today's Low
34.88
52 Week High
43.22
52 Week Low
27.89
Shares Out (MIL)
5,554.83
Market Cap (MIL)
187,920.00
Forward P/E
11.75
Dividend (Yield %)
4.49

Next Event

Q2 2020 Pfizer Inc Earnings Release

Latest Developments

More

Pfizer, BioNtech Granted FDA Fast Track Status For Two COVID-19 Vaccine Candidates

Viiv Healthcare Gives Positive Data From Study On How Best To Integrate Investigational Once-Monthly Injectable HIV Treatment In U.S. Healthcare

FDA Approves Avelumab For Urothelial Carcinoma Maintenance Treatment

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Pfizer Inc.

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.

Industry

Biotechnology & Drugs

Contact Info

235 E 42ND ST

NEW YORK, NY

10017-5703

United States

+1.212.5732323

https://www.pfizer.com/

Executive Leadership

Albert Bourla

Chairman of the Board, Chief Executive Officer

John D. Young

Chief Business Officer, Group President

Frank A. D'Amelio

Chief Financial Officer, Executive Vice President - Business Operations and Global Supply

Angela Hwang

Group President, Pfizer Biopharmaceuticals Group

Dawn Rogers

Chief Human Resource Officer, Executive Vice President

Key Stats

2.53 mean rating - 17 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

52.5K

2018

53.6K

2019

51.8K

2020(E)

49.0K
EPS (USD)

2017

2.650

2018

3.000

2019

2.950

2020(E)

2.877
Price To Earnings (TTM)
12.36
Price To Sales (TTM)
3.71
Price To Book (MRQ)
2.89
Price To Cash Flow (TTM)
8.87
Total Debt To Equity (MRQ)
80.41
LT Debt To Equity (MRQ)
55.79
Return on Investment (TTM)
12.02
Return on Equity (TTM)
9.63

Latest News

Latest News

Pfizer, BioNTech's coronavirus vaccine candidates get FDA's 'fast track' status

Pfizer Inc and partner BioNTech SE said on Monday two of their experimental coronavirus vaccines received 'fast track' designation from the U.S. health agency, speeding up the regulatory review process.

Pfizer, BioNTech's coronavirus vaccines get FDA's 'fast track' status

Two experimental coronavirus vaccines by German biotech firm BioNTech and U.S. pharmaceutical giant Pfizer have received the U.S. Food and Drug Administration's 'fast track' designation, the companies said on Monday.

RPT-Pfizer, BioNTech's COVID-19 vaccine expected to be ready for approval by year end - WSJ

BioNTech SE and Pfizer Inc's COVID-19 vaccine candidate is expected to be ready to seek regulatory approval by the end of 2020, the Wall Street Journal reported on Friday, citing the German biotech firm's chief executive officer.

Pfizer, BioNTech's COVID-19 vaccine expected to be ready for approval by year end: WSJ

BioNTech SE and Pfizer Inc's COVID-19 vaccine candidate is expected to be ready to seek regulatory approval by the end of 2020, the Wall Street Journal reported on Friday, citing the German biotech firm's chief executive officer.

BRIEF-Pfizer Inc - Pledged $100 Million To New Antimicrobial Resistance Action Fund

* PFIZER INC - PLEDGED $100 MILLION TO NEW ANTIMICROBIAL RESISTANCE ACTION FUND Source text for Eikon: Further company coverage:

BRIEF-Mission Therapeutics Says Raises $15 Million, Expands Relationship With Pfizer

* MISSION THERAPEUTICS SAYS RAISES $15 MILLION AND EXPANDS ITS RELATIONSHIP WITH PFIZER

EMERGING MARKETS-Latam assets jump on vaccine, economic recovery hopes

* Risky assets start second half of year on high note * Brazil manufacturing returns to growth in June * BioNTech, Pfizer's COVID-19 vaccine shows potential (Updates prices, adds comments, bullets) By Ambar Warrick and Shreyashi Sanyal July 1 (Reuters) - Brazil's real shot...

BioNTech and Pfizer's COVID-19 vaccine shows potential in human trial

A COVID-19 vaccine developed by German biotech firm BioNTech <BNTX.O> and U.S. pharmaceutical giant Pfizer <PFE.N> has shown potential and was found to be well tolerated in early-stage human trials, the companies said on Wednesday.

BioNTech and Pfizer's COVID-19 vaccine shows potential in human trial

A COVID-19 vaccine developed by German biotech firm BioNTech and U.S. pharmaceutical giant Pfizer has shown potential and was found to be well tolerated in early-stage human trials, the companies said on Wednesday.

BRIEF-Bioinvent International Extends Research Collaboration And License Agreement With Pfizer Inc.

* BIOINVENT EXTENDS RESEARCH COLLABORATION AND LICENSE AGREEMENT WITH PFIZER INC.

BRIEF-FDA Approves Bavencio As First-Line Maintenance Treatment For Patients With Locally Advanced Or Metastatic Urothelial Carcinoma

* FDA APPROVES BAVENCIO AS FIRST-LINE MAINTENANCE TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

BRIEF-Chobani, Pfizer And Sap Join Running List Of Companies Pulling Facebook Ads - CNBC

* CHOBANI, PFIZER AND SAP JOIN RUNNING LIST OF COMPANIES PULLING FACEBOOK ADS - CNBC Source text: https://cnb.cx/2ZmlRGL

BRIEF-Pfizer Sets Quarterly Cash Dividend Of $0.38Per Share

* SETS QUARTERLY CASH DIVIDEND OF $0.38PER SHARE Source text for Eikon: Further company coverage:

BRIEF-Aptevo Therapeutics Says Will Receive Royalty Payments From Pfizer Related To Sales Of A Rituximab Biosimilar Product, Ruxience

* APTEVO THERAPEUTICS - WILL RECEIVE ROYALTY PAYMENTS FROM PFIZER RELATED TO SALES OF A RITUXIMAB BIOSIMILAR PRODUCT, RUXIENCE

BRIEF-Pfizer Announces Start Of Four Phase 3 Clinical Trials For Investigational Vaccines

* PFIZER ANNOUNCES START OF FOUR PHASE 3 CLINICAL TRIALS FOR INVESTIGATIONAL VACCINES

Pfizer's hemophilia gene therapy shows sustained effect in early-stage study

Pfizer Inc and Sangamo Therapeutics Inc said on Thursday their gene therapy helped maintain levels of a vital protein for up to 14 months in patients with a rare genetic disorder in which blood does not clot easily.

BRIEF-Merck And Pfizer's Steglatrotm Meets Primary Endpoint

* MERCK AND PFIZER’S SGLT2 INHIBITOR STEGLATROTM (ERTUGLIFLOZIN) MEETS PRIMARY ENDPOINT IN VERTIS CV TRIAL FOR PATIENTS WITH TYPE 2 DIABETES AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE

BRIEF-Puma Biotechnology Says On June 8 Co Entered Into A Letter Agreement With Pfizer Relating To License Agreement, Originally Dated August 18, 2011

* PUMA BIOTECHNOLOGY - ON JUNE 8 CO ENTERED INTO A LETTER AGREEMENT WITH PFIZER RELATING TO LICENSE AGREEMENT, ORIGINALLY DATED AUGUST 18, 2011

BRIEF-FDA Approves Pfizer's Oncology Supportive Care Biosimilar, Nyvepria

* FDA APPROVES PFIZER’S ONCOLOGY SUPPORTIVE CARE BIOSIMILAR, NYVEPRIA™ (PEGFILGRASTIM-APGF)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up